Dear all,
We are pleased to announce the leadership teams for the AAPS Translational and Clinical Science Community, including both the Scientific Areas of Focus (Teams) and the Writing, Programming, and Scientific Exchange Activity Teams.
Below is a brief initial description of each focus area to serve as a starting point. Each team will further refine and expand these descriptions as their plans and activities evolve.
Please join us in congratulating our new leadership team in the AAPS Translational and Clinical Science Community!
Emerging Technologies and Data Science
Harnessing AI/ML, advanced analytics, and digital innovation to accelerate drug development and decision-making.
Immunogenicity
Assessing and mitigating immune responses to biotherapeutics to ensure safety, efficacy, and regulatory compliance.
New Approach Methodologies (NAM)
Advancing non-animal, human-relevant models to improve translational predictivity and enable ethical, efficient development.
New Modalities
Driving translational strategies for emerging therapeutics (e.g., oligonucleotides, mRNA, cell/gene therapies, protein degraders etc.).
Pharmacokinetics and M&S
Integrating PK/PD, drug metabolism, transporter, DDI and modeling & simulation to support translational decision-making and optimize dosing across development stages
Translational Biomarkers
Developing and applying translational biomarkers to bridge preclinical and clinical insights and enable data-driven decisions.
|
Community
|
Leadership
|
Name
|
Affiliation
|
|
Translational and Clinical Science
|
Chair
|
Hiroshi Sugimoto
|
Takeda
|
|
Vice-Chair
|
Alok Pandey
|
PBL Assay
|
|
Emerging Technologies and Data Science
|
Hiroshi Sugimoto (interim)
|
Takeda
|
|
Immunogenicity
|
Timothy Hickling
|
Quasor
|
|
New Approach Methodologies (NAM)
|
Vibha Jawa
|
EpiVax
|
|
Pooja Khanna
|
Merck
|
|
New Modalities
|
Jing Shi
|
BeOne Medicines
|
|
Nanda Balasubramanian
|
BMS
|
|
Pharmacokinetics and M&S
|
Md Masud Parvez
|
AbbVie
|
|
Fenglei Huang
|
Boehringer Ingelheim
|
|
Translational Biomarkers
|
Alok Pandey (interim)
|
PBL Assay
|
|
Writing Activity
|
Catherine Vrentas
|
Lilly
|
|
Oeystein Roed Brekk
|
Lilly
|
|
Programming Activity (OSD)
Scientific Exchange Activity
|
Carmen Fernandez-Metzler
|
PharmaCadence
|
|
Karen Quadrini
|
Prothena
|
|
Sara Geriesh
|
University of Maryland
|
|
Ishwor Poudel
|
University of Washington
|
Best regards,
Hiroshi and Alok
------------------------------
Hiroshi Sugimoto
Director
Takeda
Cambridge MA
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------